Neurizon Therapeutics Limited announced the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health and will participate in Neurizon's Board activities as Elanco's designated representative. Ms Conway is a seasoned healthcare professional with more than two decades of experience across the animal health and healthcare industries.
She joined Elanco in 2020 as Global Head of Business Development, following an extensive investment banking career with Macquarie Bank and Bank of America Merrill Lynch, where she held senior roles across Sydney, London and New York. Her experience includes significant work across the pharmaceutical and biotech sectors, executing numerous M&A transactions and capital raisings. She has deep expertise in animal health, leading major business development initiatives, the external innovation function, and a broad range of strategic transactions.
She brings a strong global network and a proven track record in advancing complex commercial partnerships, financings and M&A. As Board Observer, Ms Conway will be entitled to attend and participate in all Board and committee meetings but will not hold voting rights.
